Juno Therapeutics Inc

Juno Therapeutics — Investor Presentation (January 2017)

18 slides from Juno Therapeutics's investor presentation, Jan 9, 2017

  1. Slide 1: January 2017 Corporate Presentation

    January 2017 Corporate Presentation Juno Therapeutics Proprietary Materials Exhibit 99.1

  2. Slide 2: Forward-looking Statements, Investigational Status, and Interim Data

    Juno Therapeutics 2 Proprietary Materials Forward-looking Statements, Investigational Status, and Interim Data This presentation and the accompanying oral commentary contain forward-looking statements that involve risks, uncertainties, and assumptions. If the risks or uncertainties ever materialize

  3. Slide 3: Building the Leading T Cell Company

    Juno Therapeutics 3 Proprietary Materials Building the Leading T Cell Company  Progress with potential best-in-class CD19 product candidate and platform – JCAR017 on the market as early as 2018 – Significant advances in defining attributes that correlate with complete response in NHL – Year-end pro

  4. Slide 4: Examples of Rapid Tumor Shrinkage in Clinical Trials

    Juno Therapeutics 4 Proprietary Materials Examples of Rapid Tumor Shrinkage in Clinical Trials Day 29 After CD19 CAR T Cells NHL Patient Before CD19 CAR T Cells Day 33 After CD19 CAR T Cells CLL Patient Before CD19 CAR T Cells

  5. Slide 5: Juno Strategy: Building the Category Leader

    Juno Therapeutics 5 Proprietary Materials Combination Strategies:  PD-L1 (ongoing)  Ibrutinib (2017)  A2aR (2017/2018)  Others Juno Strategy: Building the Category Leader B-cell Malignancies Execute CD19 program:  JCAR017 in NHL – approval as early as 2018  JCAR017 in CLL – approval as early a

  6. Slide 6: JCAR015 Phase II ROCKET Trial Update

    Juno Therapeutics 6 Proprietary Materials JCAR015 Phase II ROCKET Trial Update  Clinical hold on November 22  38 total treated patients to date – 8 with flu/cy conditioning regimen – 3 treatment-related deaths – 30 with cy alone conditioning regimen – 2 treatment-related deaths – Early efficacy en

  7. Slide 7: JCAR017: Building the CD19 Category Leader

    Juno Therapeutics 7 Proprietary Materials JCAR015 JCAR017 Co-stimulatory domain CD28 4-1BB Cells T cells selected Defined composition (1:1 ratio of CD4 / CD8) Manufacturing Key steps automated and functionally closed Process design to deliver more naïve and quiescent cells Viral Vector Gamma Lenti J

  8. Slide 8: 4-1BB versus CD28 CAR T Co-stimulatory Domain Matters

    Juno Therapeutics 8 Proprietary Materials 4-1BB versus CD28 CAR T Co-stimulatory Domain Matters  Increased persistence  Increased central memory & naïve cells  Metabolic profile supporting gradual, sustained expansion  Decreased persistence  Increased effector memory cells  Metabolic profile s

  9. Slide 9: The Type of CAR T Cell Matters

    Juno Therapeutics 9 Proprietary Materials The Type of CAR T Cell Matters (1)Assumes body weight of 80 kg for adult NHL and 50 kg for pediatric ALL. (2) The dosing range for the trial is 100 - 500 million as a flat dose. (3)Total dose is dependent on body weight. Potency Disease Setting JCAR017 (tota

  10. Slide 10: NHL: Potential Best-in-class Profile

    Juno Therapeutics 10 Proprietary Materials Potential to differentiate on efficacy and safety NHL: Potential Best-in-class Profile Patient Characteristics Goal » JCAR017 NHL registration trial to initiate in 2017 with approval as early as 2018 Dose Level 1 5*107 N=19 – 22 Dose Level 2 1*108 N=2 ORR 1

  11. Slide 11: Cell Persistence + Tolerability = Ability to Combine

    Juno Therapeutics 11 Proprietary Materials Cell Persistence + Tolerability = Ability to Combine  Phase I TRANSCEND: 3 of 4 patients that relapsed had persistent CAR T cells  Case study demonstrates persistent CAR T cells can re-induce CR Complete Response at Day 29 25 20 15 5 0 0 30 60 90 120 150

  12. Slide 12: Path to Next-Generation of Defined Cell Products

    Juno Therapeutics 12 Proprietary Materials Path to Next-Generation of Defined Cell Products  Epigenetic clustering (ATACseq) analysis points to clear product differences between responders versus non-responders.  We can translate into cell physiology. responders non-responders

  13. Slide 13: CLL Emerging as a Significant Opportunity

    Juno Therapeutics 13 Proprietary Materials (1)All CLL patients have been previously treated with ibrutinib. There was 1 treatment-related death in 24 treated CLL patients to-date. Severe cytokine release syndrome = 8% (2 of 24 patients). Severe neurotoxicity = 25% (6 of 24 patients). For JCAR014, in

  14. Slide 14: Expanding the Franchise into Multiple Myeloma

    Juno Therapeutics 14 Proprietary Materials Expect BCMA CAR to enter the clinic in 1H2017 Expanding the Franchise into Multiple Myeloma Variable BCMA surface expression 3 Inadequate CAR T cell persistence 1 Complex tumor micro-environment 2  Multiple targets  Binder selection  Combinations  Fully

  15. Slide 15: Applying CARs & TCRs to Solid Organ Cancers

    Juno Therapeutics 15 Proprietary Materials Applying CARs & TCRs to Solid Organ Cancers  Heavily pretreated 50 year old male with right temporal GBM  Clinical response for 7.5 months with no Grade 3 or higher events  CAR T product candidate targeting IL13Rα2 Case Study: CAR T Therapy in GBM(1) (1)

  16. Slide 16: Automation Lowers Cost and Improves Efficiency

    Juno Therapeutics 16 Proprietary Materials  Manual process  High operating expenses  ISO 5  staff:  cost: $$$$  Closed and automated process  Defined cell process  ISO 7 / 8  staff:  cost: $$$  Closed, automated, and integrated process  1-2 machines  2-4 day manufacturing time  Cell se

  17. Slide 17: Building Capabilities

    Juno Therapeutics 17 Proprietary Materials • JuMP facility online • Closed & automated manufacturing • Defined cell product • Celgene collaboration – JCAR017 PRIME designation • JW Therapeutics – investment in China • Internal and BD opportunities • Translational medicine • $1.04 billion as of 3Q16

  18. Slide 18: Robust and Diverse CAR & TCR Pipeline

    Juno Therapeutics 18 Proprietary Materials Robust and Diverse CAR & TCR Pipeline Active Programs Description CD19: JCAR017  Pediatric ALL Phase I / II  Adult NHL Phase I CD19: Combination with PD-L1  Adult NHL Phase I CD19: JCAR014  Adult B Cell Malignancies Phase I / II  Exploratory Pathway (C

Juno Therapeutics — Investor Presentation (January 2017) on 6ix